# Arkansas Court Preserves 340B Pharmacy Restrictions

The U.S. District Court for the Eastern District of Arkansas denied AstraZeneca’s motion for summary judgment seeking to block Arkansas’s 340B Drug Pricing Nondiscrimination Act. The ruling leaves the state’s restrictions on drugmakers limiting pharmacy participation in the federal 340B drug discount program in place; the signal identifies no new solicitation or contract award.

- Pharmacies, covered entities, and pharmaceutical manufacturers operating in Arkansas may be affected by how the state restrictions shape 340B pharmacy participation and drug-distribution arrangements.
- Procurement and sourcing teams should assess whether their Arkansas 340B purchasing or pharmacy arrangements are affected by the restrictions; the ruling does not itself announce a new procurement opportunity.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Regulatory Compliance
**Published:** September 30, 2026

### Government Entities
- U.S. District Court for the Eastern District of Arkansas
- State of Arkansas

### Vendors
- AstraZeneca (Plaintiff challenging the state law)